Prof Jonathan Weber, from Imperial College London, said those on the 48-week regime "end up with much higher CD4cell count and a much lower viral load".
The researchers used a sophisticated statistical modeling technique to assess viral load and CD4cell loss in more than 2, 800 patients with HIV who were not receiving treatment.
Two specific types of immune system cell that attack invaders - CD4 T-cells and natural killer cells - increased in number with age, with a higher rate of increase in women than in men.
Eventually, he began to study an antibody called Ibalizumab that was designed to block HIV from attaching to CD4, the primary receptor used by the virus to infect a cell.